SAB Biotherapeutics (SABS) Net Cash Flow (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Net Cash Flow data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Net Cash Flow rose 403.09% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (up 283.87% YoY) and the FY2025 annual result came in at $1.8 million, up 103.83% from the prior year.
• Net Cash Flow advanced to $10.0 million in Q1 2026, from -$18.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $54.1 million in Q4 2023 to a low of -$42.5 million in Q1 2024.
• A 5-year average of -$1.1 million and a median of -$3.3 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow soared 706.03% — and 2025, when it plunged 119310.81%.
• Tracing SABS's Net Cash Flow over 5 years: stood at $6.7 million in 2022, then soared by 706.03% to $54.1 million in 2023, then slumped by 99.97% to $15539.0 in 2024, then sank by 119310.81% to -$18.5 million in 2025, then soared by 154.0% to $10.0 million in 2026.
• The last three Net Cash Flow figures came in at $10.0 million (Q1 2026), -$18.5 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.